Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor

doi:10.5493/wjem.v3.i4.100

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7923)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

436

HTML

5506

Figures (1-5)

102

Sum=6044

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1054

Download

825

Sum=1879

Nov 20, 2013 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Exp Med. Nov 20, 2013; 3(4): 100-107
Published online Nov 20, 2013. doi: 10.5493/wjem.v3.i4.100

Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor

Masaki Tabuchi, Sumio Hayakawa, Eiko Honda, Kana Ooshima, Tatsuki Itoh, Koji Yoshida, Ah-Mee Park, Hideaki Higashino, Mamoru Isemura, Hiroshi Munakata

Masaki Tabuchi, Koji Yoshida, Ah-Mee Park, Hiroshi Munakata, Department of Biochemistry, Kinki University Faculty of Medicine, Osaka-Sayama 589-8511, Japan

Sumio Hayakawa, Division of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan

Eiko Honda, Life Science Research Institute, Kinki University, Osaka-Sayama 589-8511, Japan

Kana Ooshima, Hideaki Higashino, Department of Pharmacology, Kinki University Faculty of Medicine, Osaka-Sayama 589-8511, Japan

Tatsuki Itoh, Department of Pathology, Kinki University Faculty of Medicine, Osaka-Sayama 589-8511, Japan

Mamoru Isemura, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka 422-8526, Japan

Author contributions: Tabuchi M and Hayakawa S contributed equally to this work; Tabuchi M and Hayakawa S designed studies; Tabuchi M, Hayakawa S, Honda E, Ooshima K, Itoh T, Yoshida K, Park AM, Higashino H and Isemura M performed the research; Tabuchi M, Hayakawa S and Munakata H analyzed the data; Munakata H wrote the paper.

Correspondence to: Hiroshi Munakata, Professor, Department of Biochemistry, Kinki University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama 589-8511, Japan. munakata@med.kindai.ac.jp

Telephone: +81-72-3660221 Fax: +81-72-3660245

Received: May 14, 2013
Revised: July 12, 2013
Accepted: September 18, 2013
Published online: November 20, 2013

Core Tip

Core tip: (-)-Epigallocatechin-3-gallate (EGCG) binds to transforming growth factor-β (TGF-β) type II receptor (TGFRII) and inhibits TGF-β action by interfering with the interaction between TGF-β and TGFRII. Because TGF-β is considered to be the strongest inducer of tissue fibrosis, the obtained data from this investigation suggest that EGCG may be a new therapeutic agent for organ fibrosis.